On September 24, 2025, the FDA published its final guidance titled Computer Software Assurance for Production and Quality System Software. This document replaces key sections of the previous software validation principles and introduces a modern, risk-based approach to evaluating software used in medical device manufacturing and quality management.
For manufacturers, the new framework emphasizes aligning validation efforts with the software’s intended use and associated risk. It allows for more flexible testing methods, including exploratory and context-driven approaches, and places greater responsibility on companies to assess and monitor their software suppliers. Digital records such as system logs are now recognized as valid documentation, and the use of modern technologies like cloud-based systems is explicitly supported. Overall, the guidance aims to streamline compliance efforts while encouraging innovation and maintaining regulatory integrity.
